This cream contains glutathione, a natural antioxidant that lightens the skin by neutralizing free radicals and inhibiting the production of melanin
launch expected April Coordinated global commercialization My takeaway 1 Obesity drugs = new pharma battleground This is now a head-to-head innovation race, not just market expansion 2 Small efficacy differences = huge market impact Even a few percentage points shift prescribing behavior + billions in revenue 3 Lifecycle management is critical Higher doses, new pens, expanded indications = defending blockbuster franchises 4 Broader implication Expect continued competition across: GLP-1 / incretin space Combination therapies Next-gen metabolic drugs #Pharma #Obesity #GLP1 #NovoNordisk #EliLilly #DrugDevelopment #HealthcareInnovation To view or add a comment, sign in Eli Lilly and Company's orforglipron target raised by Wolfe analyst amid strong market potential orforglipron Eli Lilly obesity Wolfe analyst has raised the price target for Eli Lilly from $1250 to $1325, citing strong long-term demand for its experimental oral obesity drug, orforglipron
doi: 10.1111/ijcp.14484
Forgive the messiness of this first post I will come back and pretty it up once I get some nice sleep in 2 Likes Jeremy December 31, 2017, 8:11pm 2 Christianmelon: Forgive the messiness of this first post I will come back and pretty it up once I get some nice sleep in Take some ALCAR too
A 2023 observational study found that individuals on GLP-1 therapy lost an average of 1218 pounds within the first three months, even among those who made no formal diet changes
Which supplements are most effective
